Agenus Non Currrent Assets Other Over Time
| AGEN Stock | USD 3.34 0.48 16.78% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Agenus Performance and Agenus Correlation. Agenus |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Agenus. If investors know Agenus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Agenus listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (11.02) | Revenue Per Share 7.808 | Quarterly Revenue Growth 0.033 | Return On Assets (0.22) | Return On Equity (12.79) |
The market value of Agenus Inc is measured differently than its book value, which is the value of Agenus that is recorded on the company's balance sheet. Investors also form their own opinion of Agenus' value that differs from its market value or its book value, called intrinsic value, which is Agenus' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Agenus' market value can be influenced by many factors that don't directly affect Agenus' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Agenus' value and its price as these two are different measures arrived at by different means. Investors typically determine if Agenus is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Agenus' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Non Currrent Assets Other Analysis
Compare Agenus Inc and related stocks such as Icosavax, Galera Therapeutics, and Marker Therapeutics Non Currrent Assets Other Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MRKR | 150 K | 32.3 K | 15 K | 15 K | 0.0 | 0.0 | 0.0 | 0.0 | (332) | (472) | (21.2 M) | 2.2 M | (17.8 M) | (16 M) | (15.2 M) |
| EWTX | 975 K | 975 K | 975 K | 975 K | 975 K | 975 K | 975 K | 975 K | 975 K | 975 K | 975 K | 3.5 M | 5.3 M | 348 K | 330.6 K |
| ADAP | 0.0 | 0.0 | 0.0 | 0.0 | (1 M) | 9.2 M | 6.6 M | 8.9 M | 8.1 M | 7 M | 4.6 M | 1.7 M | 1.6 M | 3 M | 3.6 M |
| MREO | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.0 | (56 M) | (33.2 M) | (27.1 M) | (25.9 M) | (23.4 M) | (24.5 M) |
| PIRS | (2.7 M) | (2.7 M) | (2.7 M) | 126.8 K | 126.8 K | 126.8 K | 125.7 K | 130 K | 910 K | 3.1 M | 3.3 M | 2.9 M | 1.4 M | 1.6 M | 1.1 M |
| PDSB | 63.9 K | 63.9 K | 63.9 K | 63.9 K | 160.7 K | 55.2 K | 142.9 K | 142.9 K | 142.9 K | 0.0 | 0.0 | 0.0 | 0.0 | (1.0) | (0.95) |
| LPTX | 19 K | 19 K | 19 K | 17 K | 1.3 M | 2.3 M | 2.3 M | 1.1 M | 1.5 M | 1.9 M | 1.3 M | 383 K | 1.7 M | 966 K | 1.3 M |
| VKTX | 775 | 775 | 775 | 775 | 2.3 M | 237.5 K | 560.9 K | 269.6 K | 179 K | 157 K | 77 K | 109 K | 71 K | 139 K | 132.1 K |
| TGTX | (100 K) | 438 M | (10.4 M) | 85.1 K | 712.1 K | 750.3 K | 164.4 K | 587.3 K | 1.2 M | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 1.4 M | 1.3 M |
| XFOR | 363 K | 363 K | 363 K | 363 K | 363 K | 363 K | 1.4 M | 1.3 M | 639 K | 1.9 M | 3.3 M | 1.7 M | 1.2 M | 1.4 M | 1.6 M |
| MDGL | 82 K | 631 K | 458 K | 1.4 M | 305 K | 54.0 | 54.0 | 301 K | 227 K | 1.9 M | 1.8 M | 797 K | 1.2 M | 1.4 M | 719.9 K |
| AFMD | (100 K) | (100 K) | (100 K) | (100 K) | (100 K) | 0.0 | 877 K | 1.2 M | 5.3 M | 6.4 M | 6.4 M | 6.4 M | 6.4 M | 7.4 M | 7.8 M |
| ADCT | 134 K | 134 K | 134 K | 134 K | 134 K | 134 K | 134 K | 232 K | 264 K | 368 K | 397 K | 693 K | 903 K | 711 K | 509 K |
Agenus Inc and related stocks such as Icosavax, Galera Therapeutics, and Marker Therapeutics Non Currrent Assets Other description
Assets that are not physical or tangible, expected to provide value for more than one year, and not easily converted into cash, such as long-term investments or patents.My Equities
My Current Equities and Potential Positions
| Agenus Inc | AGEN |
| Classification | Cancer Fighters |
| Location | Massachusetts; U.S.A |
| Exchange | NASDAQ Exchange |
USD 3.34
Check out Agenus Performance and Agenus Correlation. You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Agenus technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.